Alnylam Going After World's Most Expensive Drug in New Trials

  • CEO says $440,000 price on existing drug gives room to compete
  • Alnylam says experimental drug will be in late trials in 2017

Alnylam Pharmaceuticals Inc. is taking on the world’s most expensive drug, betting that its experimental treatment for a rare disease can compete in a narrow market dominated by one pricey therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.